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Abstract
Background: Mice deficient in the large zinc finger protein, ZAS3, show postnatal increase in bone mass suggesting that
ZAS3 is critical in the regulation of bone homeostasis. Although ZAS3 has been shown to inhibit osteoblast differentiation,
its role on osteoclastogenesis has not been determined. In this report we demonstrated the role of ZAS3 in bone resorption
by examining the signaling mechanisms involved in osteoclastogenesis.
Methodology/Principal Findings: Comparison of adult wild-type and ZAS3 knockout (ZAS32/2) mice showed that ZAS3
deficiency led to thicker bones that are more resistant to mechanical fracture. Additionally, ZAS32/2 bones showed fewer
osteoclasts and inefficient M-CSF/sRANKL-mediated osteoclastogenesis ex vivo. Utilizing RAW 264.7 pre-osteoclasts, we
demonstrated that overexpression of ZAS3 promoted osteoclastogenesis and the expression of crucial osteoclastic
molecules, including phospho-p38, c-Jun, NFATc1, TRAP and CTSK. Contrarily, ZAS3 silencing by siRNA inhibited
osteoclastogenesis. Co-immunoprecipitation experiments demonstrated that ZAS3 associated with TRAF6, the major
receptor associated molecule in RANK signaling. Furthermore, EMSA suggested that nuclear ZAS3 could regulate
transcription by binding to gene regulatory elements.
Conclusion/Significance: Collectively, the data suggested a novel role of ZAS3 as a positive regulator of osteoclast
differentiation. ZAS3 deficiency caused increased bone mass, at least in part due to decreased osteoclast formation and
bone resorption. These functions of ZAS3 were mediated via activation of multiple intracellular targets. In the cytoplasmic
compartment, ZAS3 associated with TRAF6 to control NF-kB and MAP kinase signaling cascades. Nuclear ZAS3 acted as a
transcriptional regulator for osteoclast-associated genes. Additionally, ZAS3 activated NFATc1 required for the integration of
RANK signaling in the terminal differentiation of osteoclasts. Thus, ZAS3 was a crucial molecule in osteoclast differentiation,
which might potentially serve as a target in the design of therapeutic interventions for the treatment of bone diseases
related to increased osteoclast activity such as postmenopausal osteoporosis, Paget’s disease, and rheumatoid arthritis.
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Introduction
The large zinc finger protein, ZAS3, is a member of the ZAS/
HIVEP/schnurri (shn) protein family, which encodes unusually large
transcriptional proteins of more than 250 kDa in size [reviewed in
1,2]. ZAS3 has been cloned by screening expression cDNA
libraries using the V(D)J recombination signal sequences or the
calcium-binding protein S100A4/mts-1 gene enhancer [3,4]. The
ZAS proteins are named after a composite protein structure, the
ZAS domain, which consists of a pair of consecutive C2H2 zinc
fingers, an acidic domain and a ser/thr-rich region [2]. Zinc
fingers and acidic domains are known structures for DNA binding
and protein-protein interaction, respectively. Each ZAS protein
contains two widely separated ZAS domains. Individual ZAS
domains have been shown to bind specifically to cis-acting gene
regulatory elements with a consensus sequence GGGGNNNNCC
[2].
Cumulating evidence suggests that ZAS proteins play diverse
cellular functions. Initial studies focusing on the DNA binding and
transcriptional activities of the ZAS proteins have identified several
ZAS target genes involved in growth, immunity, and development,
including interferon-b [5], collagen type II [6], somatostatin type
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proteins associate with adaptor molecules to regulate signal
transduction of the Smad complex in the bone morphogenetic
protein (BMP) and transforming growth factor (TGF)-b pathways,
and TRAF2 in the TNFa signaling cascades [9–12]. ZAS3 can
also associate with the transcription factor c-Jun to augment AP-1-
mediated IL-2 expression [13]. Recently, ZAS proteins have also
been shown to affect protein stability. ZAS2 (Shn-2) associates with
chloride intracellular channel 4 to stabilize phospho-Smad2/3,
whereas ZAS3 associates with the E3 ubiquitin ligase WWP1 to
facilitate the degradation of Runx2, the principal transcriptional
regulator of osteoblast differentiation [10,14]. The diverse
functions of the ZAS proteins in the regulation of transcription,
signal transduction and protein turnover suggest that they likely
play important roles in many physiological processes.
To investigate the physiological functions of the ZAS proteins,
single and double knockout mice for ZAS2 and ZAS3 have been
generated, which reveal that both genes are important for
postnatal bone development and endochondral ossification [14–
17]. With respect to bone homeostasis, the lack of ZAS2
suppresses both osteoclast and osteoblast activities, and generally,
the suppression of osteoblast activities overrides that of osteoclasts
as there is an overall reduction of bone mass in ZAS22/2 mice
[16]. On the other hand, adult ZAS32/2 mice have a higher
bone mass due to augmented osteoblast activity [14,15].
Skeletal homeostasis, including adult bone mass, is determined
by the balanced activities of two specific cell types; bone forming
osteoblasts and bone resorbing osteoclasts. Therefore, the
possibility that the increased bone mass in ZAS32/2 mice is
due to osteoclast deficiency exists. We speculated that ZAS3 might
regulate osteoclasts based on the following considerations: (i) ZAS3
is expressed in monocytes/macrophages, which share a common
hematopoietic progenitor with osteoclasts [3]; (ii) ZAS3 can affect
gene expression by association with c-Jun [13], an essential
transcription factor for osteoclastogenesis [18,19]; and (iii) The
DNA binding activities of NF-kB and AP-1, important transcrip-
tional mediators for osteoclastogenesis, exhibit tissue-specific
alterations in ZAS32/2 mice [15,20]. Therefore in this report,
we have characterized osteoclasts in ZAS32/2 mice, and
examined the role of ZAS3 in osteoclastogenesis. We showed that
(i) bones of adult ZAS32/2 mice had fewer osteoclasts; (ii) ZAS3
was upregulated upon osteoclastogenesis of bone marrow
macrophages (BMM) as well as of RAW264.7 pre-osteoclasts;
(iii) sRANKL induced inefficient differentiation of ZAS32/2
BMM into osteoclast-like cells (OLCs) as compared to wild-type
(WT) BMM; and (iv) forced expression of ZAS3 promoted,
whereas silencing of ZAS3 inhibited, sRANKL-induced differen-
tiation of RAW 264.7 preosteoclasts into osteoclasts and the
expression of osteoclast-associated genes. Hence, the data
identified a novel physiological function of ZAS3 in osteoclast
biology and in adult bone remodeling.
Results
ZAS32/2 mice exhibit thicker bones with increased
fracture resistance
Mice (ZAS3 +/+, +/2, and 2/2) were generated by
heterozygous crosses. Biomechanical analysis (load to fracture;
Fx) using three-point bending revealed that the femoral diaphyseal
bone strength of adult male ZAS32/2 mice (30.88611.76 N) was
significantly greater than those of ZAS3 WT (17.8666.13) and
their heterozygous littermates (17.9865.61). Increased bone
strength was observed in both male and female ZAS32/2 mice
(Fig. 1A and Table 1). Furthermore, the outer femoral diameters
of ZAS32/2 male mice (1.9260.16 mm) were larger than control
mice (1.6160.08 mm +/+ and 1.7060.10 mm +/2), whereas the
inner diameters (0.5560.24 mm 2/2) were smaller than those of
the controls (0.860.04 mm +/+, and 0.8160.10 mm +/2),
culminating in significantly larger bone areas in ZAS32/2 mice
(2.6460.66 mm
2 2/2; 1.5060.19 mm
2 +/+; and 1.726
0.30 mm
2 +/2). When force to failure was proportioned to area,
there was no significant difference in the stresses among the
samples (Table 1), suggesting that the intrinsic properties of the
bones were not altered by ZAS3 deficiency. Increase in bone
strength and changes in bone dimensions were observed in both
male and female ZAS32/2 mice.
Histomorphometric imaging using micro-computed tomogra-
phy (mCT) showed increased trabecular bone and cortical bone
thickness in adult ZAS32/2 mice (Fig. 1B and 1C). Additionally,
histological analysis of femoral bones with von Kossa’s staining
showed that the ZAS32/2 mice had greater amounts of
mineralized bone in the spongiosa, as compared to the WT mice
(Fig. 1D). Hence, the increased thickness and mineralization of the
cortical and trabecular bone could be additional factors contrib-
uting to the increased bone strength of ZAS32/2 mice.
Dynamic femoral bone parameters at different ages of
WT and ZAS32/2 mice
Histological sections of femurs were prepared to evaluate the
bone phenotypes and bone formation parameters in adult
ZAS32/2 and ZAS3+/+ control mice, from ages 3 months to 6
months (Table 2). At all ages examined, the volume, number and
thickness of the trabecular bones of the ZAS32/2 mice were
significantly (p,0.05) higher than those of sex-matched control
littermates. Consequently, the trabecular separation was narrower
in ZAS32/2 mice. Bone volume fraction and trabecular
separation correlated with hardness [22]. Therefore, they could
be factors contributing to the increased bone strength in ZAS32/2
mice (Fig. 1A). In dynamic measurements, there were no significant
differences in the mineral apposition rate between ZAS32/2 and
control mice. However, the ratio of mineralization surface to bone
surface and the bone formation rate, measures of total bone
anabolic activity were slightly decreased in the ZAS32/2 mice,
most notably at 3 months. Whereas a robust phase of bone growth
in neonatal ZAS32/2 mice, occurring between ages 1 week and 2
weeks, contributed to high bone mass [14], our data suggested
that other factors might maintain the high bone mass in adult
ZAS32/2 mice.
Femurs of adult ZAS32/2 mice have decreased numbers
of osteoclast
Adult bone remodeling is a balance between bone formation
and bone resorption. Next, we compared the abundance of
osteoclasts between ZAS32/2 and control mice to determine
whether the high bone mass may be due to defective osteoclasts,
and hence decrease in bone resorption. Histological bone sections
of 1 month and 4 months old mice were stained with H&E or for
TRAP, an enzyme highly expressed in osteoclasts (Fig. 2A–H).
The intensity and amount of TRAP staining in ZAS32/2 mice
were less than ZAS3+/+ mice at both ages. The distribution of
TRAP was most limited in 4-month-old ZAS32/2 bones
(Fig. 2H), at a time when the trabeculae and cortices of the
ZAS32/2 bones were approximately twice the thickness of the
control ZAS3 +/+ mouse. A higher magnification showed more
abundant, larger osteoclasts with more TRAP lining the
trabecular bones of 4-month-old WT mice than ZAS32/2 mice
(Fig. 2I, J).
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transcription factor in osteoclast differentiation, was significantly
downregulated in ZAS32/2 bone marrow stromal cells comparing
to controls (Fig. 2K). Similarly, the activated and phosphorylated
forms of p38and c-Jun were suppressed in ZAS32/2 bone marrow
cells. These MAP kinases and transcription factors are essential for
sRANKL-induced osteoclast differentiation [18,19, and 20 for a
review]. The decreased expression of these major osteoclast
regulators in ZAS32/2 bone marrow stromal cells was in
agreement with the histological findings which revealed very few
osteoclastsinbonesofadult ZAS32/2mice (Fig.2J).Inall,thedata
showed that adult ZAS32/2 mice had less osteoclasts than control
mice. Defective osteoclasts should lead to decreased bone
resorption, resulting in mild osteopetrosis in adult ZAS32/2 mice.
Expression and subcellular localizations of ZAS3 associate
with osteoclastogenesis of bone marrow precursors
Previously, we have shown that ZAS3 is expressed in
macrophages [3]. However, its expression in osteoclast precursors
and during osteoclastogenesis has not been determined. Bone
marrow stromal cells isolated from ZAS3+/+ and ZAS32/2 mice
were differentiated into BMM by incubating with M-CSF (50 ng/
ml) for 3 days, and then osteoclast differentiation was induced by
the addition of sRANKL. Western blot analysis revealed dramatic
increase of ZAS3 proteins after stimulating WT BMM with
sRANKL (50 ng/ml) for 3 days (Fig. 3A). In addition, immuno-
histochemical analysis showed alteration of the subcellular
localization of ZAS3 during osteoclastogenesis. In mononuclear
BMM, ZAS3 was mainly observed in the nucleus (indicated with a
white arrow in Fig. 3B). However, in cells with two nuclei (after the
first cell fusion), not only was the nuclear expression of ZAS3
increased dramatically, it was also observed in the cytoplasm.
Notably, some cytoplasmic ZAS3 was observed at the cell
membrane (indicated with a yellow arrow in Fig. 3B).
Osteoclast differentiation of BMM was monitored by staining
for the presence of TRAP and changes in cell morphology
(Fig. 3C). After 4 days of sRANKL stimulation, more than 50% of
the WT BMM had differentiated into TRAP positive osteoclast-
like cells (OLCs) and some with 3 or more nuclei, whereas only
10% of the ZAS32/2 BMM were TRAP positive (Fig. 3C, upper
panels). At day 6, most WT BMMs had differentiated into giant
TRAP positive OLCs, often with more than 10 nuclei (Fig. 3C,
lower panels). On the contrary, the number of OLCs derived from
ZAS2/2 BMM was considerably much less, only ,10% of that of
WT (Fig. 3D, p,0.05). In addition, such OLCs were generally
smaller and with fewer (3 to 4) nuclei (Fig. 3C, lower panels).
Consequently, Western blotting showed that after incubation with
sRANKL for 4 days, ZAS3+/+ and ZAS3+/2 BMMs produced
more TRAP and cathepsin K (CTSK), enzymes required for
osteoclastic bone resorption, than ZAS32/2 BMMs (Fig. 3E).
Taken together, the data showed that the expression of ZAS3 was
associated with osteoclast differentiation and that ZAS3-deficiency
blocked osteoclastogenesis. Therefore, ZAS3 was essential for
osteoclast differentiation and function from bone marrow
osteoclast precursors.
Regulation of ZAS3 during osteoclastogenesis of RAW
264.7 cells
Next, we examined the expression of ZAS3 in RAW 264.7
preosteoclasts during sRANKL-mediated osteoclastogenesis.
Figure 1. The bones of adult ZAS3 knockout mice have increased bone strength, thickness, and mineralization. (A) Biomechanical
properties of femurs were evaluated by three-point bending test. Load to fracture (Fx) was significantly increased in both male and female ZAS32/2
mice compared to +/+ and +/2 control mice (*, p,0.05). (B) & (C) Micro-CT reconstruction images of femora of 4-month-old mice. Bar represents
1 mm. (D) Sagittal section of distal femora from 5-month-old mice stained with von Kossa’s method plus MacNeal tetrachrome counterstain.
Mineralized bone was stained black and collagen type 1 was stained light blue. Bar represents 1 mm. +/+ ZAS3 WT mice, 2/2 ZAS3 KO mice, and +/2
heterozygous ZAS3 mice.
doi:10.1371/journal.pone.0017161.g001
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TRAP expression during osteoclastogenesis of RAW 264.7 cells.
Unstimulated RAW 264.7 cells were small, round, mononuclear,
and without detectable TRAP expression. At day 2 of sRANKL
(50 ng/ml) stimulation, most cells had assumed a fibroblast-like
morphology, developed cytoplasmic extensions, and expressed low
levels of TRAP. Thereafter, TRAP expression increased and OLC
phenotype progressed rapidly, and at day 6, most cells had
differentiated into multinucleated TRAP positive OLCs. Western
blot analysis showed significant increase in ZAS3 expression after
6 days of stimulation with sRANKL (Fig. 4B). In addition,
immunohistochemical analysis showed that as observed in BMM,
the subcellular localization of ZAS3 in RAW 264.7 cells gradually
changed during osteoclastogenesis, transiting from the nucleus to
the cytoplasm (Fig. 4C–E). Taken together, the expression of
ZAS3 was increased and its subcellular localization changed from
nuclear to cytoplasmic upon osteoclastogenesis of RAW 264.7
cells. Similar changes in ZAS3 expression that were also observed
during osteoclastogenesis of primary bone marrow cells (Fig. 3A,
B) suggested such patterns of ZAS3 expression probably associate
with differentiation of diverse osteoclast precursors.
Silencing of ZAS3 suppresses osteoclastogenesis and its
forced expression promotes osteoclastogenesis in RAW
264.7 cells
To delineate the molecular mechanism by which ZAS3
regulates osteoclastogenesis, we silenced ZAS3 expression in
RAW 264.7 cells by transfecting a pool of four short interference
RNAs (siRNAs) that targeted different protein coding regions of
the ZAS3 transcripts and determined how that might affect
sRANKL-induced osteoclastogenesis. Four days after transfection
and incubation with sRANKL (50 ng/ml), the relative levels of
ZAS3 transcripts and proteins in RAW 264.7 cells were
significantly decreased by ZAS3 siRNA (at 5 mM and 10 mM
concentrations) than those of scramble controls (Fig. 5A, B).
Notably, the expression of TRAP and CTSK was also decreased
in the ZAS3 silenced samples, suggesting a positive relationship
between the expression of ZAS3 and these two crucial osteoclast-
associated genes. As a negative control, the expression of b-actin
was not affected by ZAS3 silencing (Fig. 5A, B). In addition, the
number of sRANKL-induced OLC formed at day 6 was
significantly reduced in the ZAS3 silenced cells, as compared to
scramble siRNA transfected controls (Fig. 5C). Because c-Jun, a
component of AP-1 that is important for osteoclastogenesis, was
downregulated in ZAS32/2 bone marrow cells (Fig. 2B), we
performed EMSA and showed that nuclear extracts prepared from
ZAS3 silenced RAW 264.7 cells yielded significantly less AP-1-
protein complexes than control samples (Fig. 5D). Hence, the data
showed that silencing ZAS3 in RAW 264.7 cells inhibited
osteoclastogenesis and the expression of important osteoclast-
associated gene products, TRAP, CTSK and AP-1.
Next we determined whether overexpression of ZAS3 would
promote osteoclastogenesis. RAW 264.7 cells were stably trans-
Table 2. Dynamic femoral bone parameters of adult ZAS3 WT and KO mice.
Age
months Genotype BV/TV (%) Tr. N. (mm
21) Tr. Sp. (mm) Tr. Th. (mm)
MAR
(mcm/day) MS/BS (%)
BFR/BS
(mcm/day)
6 WT 5.2861.3 0.7660.16 15666218 68.15612 1.6560.3 14.6966.7 27.7569.2
KO 58.2563.5 1.7960.27 252.68611 393.94687 1.6360.08 13.2864.7 22.8466.6
p values 2.83E-07 0.001127 6E-05 0.002883 0.88509 0.755703 0.441597
5 WT 6.8663.2 0.8260.26 1106.10655 86.5469.07 1.5660.36 31.0668.3 52.98631.1
KO 25.0269.6 1.6460.37 528.906291 157.00633 1.5260.19 11.17610.9 30.4365.46
p values 0.011718 0.011786 0.028044 0.023907 0.895211 0.027467 0.390637
3 WT 4.8561.82 0.7260.18 1798.796501 64.3068.09 2.4260.32 32.45611.81 111.4612.5
KO 53.75626 1.8260.38 258.086114 431.77633 1.7060.28 19.9863.3 58.8164.9
p values 0.010885 0.002416 0.00389 0.00118 0.069244 0.018564 0.06453
BV/TV, bone volume/total volume; Tr.N, trabecular number; Tr.Sp, trabecular separation; Tr.Th, trabecular thickness; MAR, mineral apposition rate; MS/BS, mineralization
to bone surface; BFR/BS, bone formation rate; CS, cross section; and OC/BS, number of osteoclast/bone surface.
doi:10.1371/journal.pone.0017161.t002
Table 1. Biomechanical property and dimensions of femur
bones.
ZAS3+/+ ZAS3+/2 ZAS32/2
male female male female male female
Load to Fracture (N)
average 17.86 14.19 17.98 15.73 30.88 34.10
STD 6.13 3.39 5.61 4.33 11.77 12.44
p values 0.96 0.23 0.0012 6.83E-07
Outer dimensions (mm)
average 1.61 1.50 1.70 1.58 1.92 1.84
STD 0.08 0.087 0.11 0.079 0.16 0.052
p values 0.028 0.24 5.30E-07 0.0027
Inner dimensions (mm)
average 0.83 0.80 0.82 0.79 0.55 0.635
STD 0.043 0.095 0.10 0.095 0.25 0.033
p values 0.29 0.93 5.6E-05 8.14E-05
AREA (mm
2)
average 1.51 1.26 1.72 1.47 2.64 2.34
STD 0.19 0.19 0.31 0.19 0.66 0.15
p values 0.059 0.012 2.34E-06 1.23E-13
Stress to fracture (N/mm
2)
average 11.44 11.41 10.64 10.76 11.47 14.58
STD 3.74 2.82 2.45 2.63 2.52 5.05
p values 0.39 0.47 0.76 0.056
doi:10.1371/journal.pone.0017161.t001
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complete ZAS3 protein (from amino acids 106 to 2013 of the 2384
residues). Because osteoclasts are formed by cell fusion, cell density
is also critical for the formation of multinucleated OLC.
Therefore, three titrations of cells (500, 1000, and 2500 cells per
well) were cultured with sRANKL for 6 days. In all cases, the
numbers of OLC formed by ZAS3 transfectants were higher, by
2–10 fold, than control cells transfected with the empty vector
(Fig. 6A). Western blot analysis showed that endogenous ZAS3
expression in parental RAW 264.7 was low and was significantly
induced by sRANKL at day 8 (Fig. 6B). On the other hand, the
expression of recombinant ZAS3 proteins in the ZAS3 transfec-
tants was readily detectable even in unstimulated cells. Recombi-
nant ZAS3 was not induced by sRANKL because its expression
was under the control of a heterologous CMV promoter. In
addition, the expression of CTSK and TRAP was generally much
higher in ZAS3 overexpressing cells, supporting our notion that
ZAS3 positively regulates these osteoclastic genes. As a control of
protein loading, Western blot analysis was performed with heat
shock protein 90 (HSP90) antibodies. Consequently, we also
examined the expression of several important signaling molecules
and transcription factors in RANK signaling, and found that
ZAS3 further enhanced the RANKL-induced expression of
TRAF6, RelB, c-Fos and c-Jun (Fig. 6C).
The expression of TRAP was positively associated with of
ZAS3. TRAP expression was higher in ZAS3 overexpressing
RAW 264.7 cells (Fig. 6B), and was lower in ZAS32/2 BMM
(Fig. 3C & E) and in ZAS3 silenced RAW 264.7 cells (Fig. 5B).
Therefore, we performed DNA-protein interaction analysis of
ZAS3 and the TRAP gene regulatory element to evaluate whether
ZAS3 regulates transcription of TRAP. The proximal enhancer of
TRAP, located at nucleotides 26 to 55 upstream of the
transcription start site containing binding sites for MITF, PU.1
and EOS, has been characterized [23]. An inspection of that
enhancer sequence revealed a putative ZAS3 binding site,
GGGGNNNNCC [2]. In EMSA, nuclear extracts of RAW
264.7 control and
32P-labeled TRAP enhancer sequence yielded
three major DNA-protein complexes, designated as C1, C2 and
C3 (Fig. 6D, lane 2). Nuclear extracts prepared from ZAS3
overexpressing cells yielded an additional complex, C4, with a gel
mobility slightly faster than C2 (lane 3 and indicated with a black
arrow). To determine whether those DNA-protein complexes
contained ZAS3, antibody supershift assays were performed. The
addition of ZAS3 antibodies to the binding reaction abolished the
formation of C2 and C4 complexes, suggesting that they contained
ZAS3. Most likely, complex C2 contained endogenous ZAS3
protein, whereas complex C4 contained recombinant ZAS3
protein. Taken together, these experiments demonstrated that
Figure 2. Adult ZAS3 knockout mice exhibit decreased number of osteoclasts. Sagittal sections of femora from 1-month-old mice (A to D)
or 4-month-old mice (E to H) stained with H & E (A, C, E and G) or stained for TRAP (B, D, F and H). (I) and (J) Higher magnifications of femora of 4-
month-old mice stained with TRAP. Note that the number of osteoclasts (cells stained red and indicated with arrows) in WT mice (I) was more
abundant than that of KO mice (J). (K) Western blot analysis of protein lysates of bone marrow stromal cells with indicated antibodies. +/+ ZAS3 WT
mice, 2/2 ZAS3 KO mice, and +/2 heterozygous ZAS3 mice.
doi:10.1371/journal.pone.0017161.g002
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transcriptional function to promote expression of osteoclastic genes
and osteoclastogenesis.
ZAS3 associates with TRAF6
Finally, we examined the cytoplasmic function of ZAS3. Based
on the membrane proximity of ZAS3 during osteoclastogenesis
(shown with a yellow arrow in Fig. 3B) and the ability of ZAS3 to
associate with TRAF2 [12], we determined whether ZAS3 could
associate with TRAF6, the major member of the TRAF protein
family involved in osteoclastogenesis [24]. RAW264.7 cells were
stimulated with sRANKL (50 ng/ml) for 2 days, and immuno-
precipitation (IP) experiments of total cell lysates were performed
with ZAS3, TRAF6 or control IgG antibodies. The presence of
TRAF6 in the eluate of the IP experiments using ZAS3 antibodies
and vice versa, suggested that ZAS3 interacted with TRAF6 (Fig. 7A,
B). Furthermore, initial IP experiments using unstimulated cells
did not detect such protein-protein interactions, suggesting that
the interaction of ZAS3 and TRAF6 was induced by RANKL.
ZAS3 could associate directly with TRAF6 or via other adaptor
molecules. In support of the former notion, an inspection of the
ZAS3 protein sequence revealed six putative TRAF6-binding
motifs [Pro-X-Glu-X-X-(Ar/Ac), Ar an aromatic and Ac an acidic
residue] in the ZAS3 protein [25]. Figure 7C shows their amino
acid sequence alignment and the locations of the six TRAF6
binding motifs in the ZAS3 protein. In all, the results of the co-IP
experiments and the presence of putative TRAF6 binding site in
the ZAS3 protein suggested that ZAS3 may directly associate with
TRAF6.
Discussion
Present findings demonstrate that ZAS3, a large zinc finger
protein, is a critical regulator of bone resorption and controls bone
mass via activation of osteoclasts. This is evident from the
observations that the bones of adult ZAS32/2 mice are thicker
and more resistant to fractures. The biomechanical properties
contributing to the increased bone strength in ZAS32/2 mice
likely are the summation of several factors, including increased
Figure 3. ZAS3 is essential for RANKL-mediated osteoclastogenesis of bone marrow precursors. (A) Western blot analysis of total protein
lysates prepared from bone marrow macrophages (BMM) cultured without (2) or with (+) sRANKL (50 ng/ml) for 3 days. Bone marrow aspirates
isolated from WT mice were cultured in complete medium with M-CSF (50 ng/ml) for 3 days, and non-adherent cells were harvested and further
cultured with M-CSF (50 ng/ml) and sRANKL (50 ng/ml) for 3 days. (B) Immunohistochemical analysis of ZAS3 (red) in bone marrow macrophages
(BMM) cultured with M-CSF and sRANKL (50 ng/ml each) at an early phase of osteoclastogenesis. White arrow indicates a mononucleated cell in
which ZAS3 shows prominently nuclear localization. Yellow arrow highlights the membrane proximity of ZAS3 in a cell that contained two nuclei and
therefore, had undergone the first cell fusion. Nuclei were stained with DAPI (blue). (C) TRAP staining of BMM cultured in the presence of M-CSF and
sRANKL (50 ng/ml each). More TRAP+ (cells stained red) and OLC were observed from ZAS3+/+ than ZAS32/2 BMM at day 4 (upper panels) and day 6
(lower panel). At day 6, most ZAS3+/+ BMM had differentiated into large multinucleated TRAP positive cells while ZAS32/2 BMM was inefficient to do
so and failed to form large spreading TRAP+ OLC. Scale bar, 100 mm. Data were representatives of 1 out of 3 independent experiments. (D) Bar charts
showing the number of TRAP+ multinucleated OLC (more than 3 nuclei) formed in response to sRANKL and M-CSF stimulation (initially plated 5000
cells per well of an 8 well slide). Data were expressed as the mean 6 SD from 3 independent experiments. (E) Western blot analysis of protein lysates
of BMM cultured with M-CSF and sRANKL for 6 days with indicated antibodies. +/+ ZAS3 WT mice, 2/2 ZAS3 KO mice, and +/2 heterozygous ZAS3
mice.
doi:10.1371/journal.pone.0017161.g003
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bone volume and number, and decreased in trabecular separation.
In bone, increase in the osteoblast activity contributes to increase
in bone formation and bone mass in neonatal ZAS32/2 mice
[14]. Here we show that osteoclasts in adult ZAS32/2 mice are
defective, which should lead to decrease in bone resorption, and
consequently, higher bone mass. The decrease in the number of
osteoclast may lead to decreased bone resorption, and may
augment the deposition of more densely mineralized bone, with
reduced porosity and the temporary deficit of bone that occurs
between bone resorption and formation. Together with the role of
ZAS3 in osteoblasts [14], our findings suggest that ZAS3 also
regulates osteoclast differentiation and thus must be critical in
postnatal skeletal remodeling.
Orthologous ZAS proteins from humans to lower eukaryotes
have been shown to be involved in skeletal development. For
examples, sma-9 in nematodes regulates pathways of defective
body length-1 (DBL-1) [27] and schnurri (Shn) in Drosophila
regulates decapentaplegic (dpp), the homologue of vertebrate
BMPs [28]. BMPs play key roles in both osteoblast proliferation
and differentiation, as well as in osteoclast differentiation
[reviewed in 29]. In mice, gene knockout experiments show that
the ZAS proteins are required for both osteoblast and osteoclast
development [14–16], and together this protein family might
orchestrate postnatal skeletal development. Although the genera-
tion of ZAS1 knockout mice has not been reported, ZAS1 has also
been shown to inhibit the expression of the type II collagen, a
major extracellular matrix protein in cartilage [6]. Recently,
double knockout mice for ZAS2 (Shn2) and ZAS3 (Shn3) have been
generated, and they exhibit impaired growth plate maturation
during endochondral ossification and massively elevated trabecu-
lar bone formation [17]. Earlier findings that ZAS3 augments
osteoblast bone formation together with our findings that ZAS3 is
crucial for osteoclast bone resorption suggest that ZAS3 plays an
integral role in adult bone remodeling.
We have observed that the lack of ZAS3 in bone marrow
precursors and silencing of ZAS3 in preosteoclast directly suppress
RANKL-mediated osteoclast differentiation. Conversely, forced
expression of ZAS3 promotes osteoclastic differentiation. These
observations along with reduction of osteoclasts in bones of
ZAS32/2 mice strongly point to an essential role of ZAS3 in
osteoclastogenesis. We further confirmed the role of ZAS3 in
sRANKL mediated induction of osteoclast differentiation by
demonstrating the ability of ZAS3 to bind to the TRAP promoter
and associates with TRAF6. These experiments suggest that ZAS3
might have multiple functions in regulating osteoclastogenesis. It
serves as a transcription factor to regulate osteoclast-associated
gene transcription and as a signaling molecule to regulate the
RANK/RANKL signaling pathway. Our notion can be further
supported by the increased expression of ZAS3 and its presence in
Figure 4. Expression and subcellular localization of ZAS3 associate with osteoclastogenesis of RAW 264.7 preosteoclasts. (A)
Morphological changes and increase in TRAP expression of RAW264.7 cells upon sRANKL-mediated osteoclastogenesis. RAW 264.7 cells were cultured
for 0, 2, 4 or 6 days and stained for TRAP. Scale bar, 50 mm and arrows show representative TRAP+ cells. (B) Western blot analysis to show the
presence of ZAS3 in RAW 264.7 cells at days 0, 2, 4 and 6 incubated with sRANKL (50 ng/ml). The protein filter was also incubated with histone H1
antibodies as a loading control. (C) Immunohistochemical fluorescence microscopy showing the expression of ZAS3 in RAW 264.7 cells at various
stages of osteoclast differentiation. Number shown was the number of nucleus or nuclei presence in the cell indicated. During osteoclastogenesis,
multinucleated giant cells are progressively formed by cell fusion. Therefore, increasing number of nuclei represented cells were at more advanced
stage of osteoclastogenesis.
doi:10.1371/journal.pone.0017161.g004
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mediated osteoclastogenesis of primary bone marrow precursors as
well as RAW 264.7 preosteoclasts. The similar pattern of gene
expression of ZAS3 in both cells suggests this phenomenon could
be a general mechanism by which ZAS3 regulates osteoclast
differentiation. Many components in RANK signaling central to
osteoclastogenesis, including NFATc1, phospho-p38 and c-Jun,
are downregulated in the absence of ZAS3. On the other hand,
the expression of key osteoclast-associated molecules, such as
enzymes (CTSK and TRAP), signaling molecules (TRAF6 and p-
p38) and transcription factors (RelB, c-Fos and c-Jun, and
NFATc1) are enhanced by ZAS3 upon RANKL-induction. The
data suggest that ZAS3 is important in multiple aspects of
osteoclast formation and activity, including differentiation, survival
and bone resorptive functions.
In conclusion, our studies demonstrate that ZAS3 is a crucial
regulator of bone mass, is required for bone remodeling, and
regulates bone resorption via induction of osteoclast differentiation
and function. The significance of ZAS3 in RANK signaling is
evident from the phenotype of adult ZAS3 deficient mice, which
have thicker bones and fewer osteoclasts. Using RAW 264.7
preosteoclast cells, we further showed that forced expression of
ZAS3 promotes osteoclastogenesis, while silencing of ZAS3 results
in a significant reduction of RANKL’s ability to induce
osteoclastogenesis and expression of osteoclastic genes, including
NFATc1, the master regulator of osteoclast differentiation [31,32].
Based on the expression and dynamic localization of ZAS3 in the
cytoplasm and nucleus, and its ability to associate with specific
proteins (such as TRAF6 shown here and c-Jun [13]) and bind to
cis-acting gene regulatory DNA elements (the TRAP promoter
shown herein), we propose that ZAS3 should have multiple
cytoplasmic and nuclear targets to modulate osteoclastogenesis via
the RANK signaling cascade either directly or via activation of
NFATc1 (Fig. 8). Starting from the RANK receptor proximate
adaptor protein TRAF6, overexpression of ZAS3 leads to the
upregulation of TRAF6 which could intensify RANK signaling. In
addition, the fact that ZAS3 also associates with an E3 ubiquitin
ligase, WWP1, tempts us to speculate that if cytoplasmic ZAS3
Figure 5. Silencing of ZAS3 inhibits RANKL-mediated osteoclastogenesis in RAW 264.7 cells. RAW264.7 cells were transfected with (1 mM,
5 mM, or 10 mM) scramble siRNA or a pool of four ZAS3 siRNA and incubated with complete medium supplemented with sRANKL (50 ng/ml). RNA and
total protein lysates were prepared 4 days later and analyzed by (A) RT-PCR and (B) Western blot analysis using gene-specific primer sets and
antibodies, respectively. (C) The above transfected cells were incubated with sRANKL (50 ng/ml) for 6 days and the numbers of OLC (TRAP positive
cells with three or more nuclei) were counted. The percentage of OLC formed by scramble siRNA transfected cells was tentatively assigned as 100.
Cells transfected with ZAS3 siRNA formed relatively much less (10% versus scramble) OLC. Data are expressed as mean 6 SD from three independent
experiments. (D) RAW 264.7 cells were mock transfected, transfected with scramble siRNA, or with ZAS3 siRNA, and incubated with sRANKL (50 ng/ml)
for 4 days. Subsequently, EMSA was performed with nuclear extracts and
32P AP-1 consensus sequences. The amount of siRNA (1, 5, and 10 in
micromoles) used in transfection is shown on the top of the lanes.
doi:10.1371/journal.pone.0017161.g005
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activation of TRAF6 through polyubiquitination [14]. Polyubi-
quitinated TRAF6 recruits TAB2/3, which in turn may activate
TAB1/TAK1 and ultimately NFATc1 via: (i) assembly of the IKK
complex, ubiquitination and degradation of IkB, and translocation
of p50/p65 into the nucleus to activate the transcription of
NFATc1 [31]; (ii) activation of AP1 via MAP kinase signaling
cascades to induce phosphorylation of p38 and assembly of c-Jun/
c-Fos, which is shown to be critical for NFATc1 activation and
autoactivation [18,19,30]; and (iii) mobilization of intracellular
calcium, probably through the calcium binding protein S100A4/
mts1 that is a ZAS3 target gene [4], which results in the activation
of calcineurin that dephosphorylates NFATc1 and allowing its
translocation into the nucleus. Furthermore, when translocated
into the nucleus, ZAS3 binds to the promoter regions of osteoclast-
associated genes, such as TRAP, or as a part of the transcriptional
complex that contains NFATc1 and AP-1 for the activation of
osteoclast-specific genes, such as CTSK, TRAP, and NFATc1.
Based on these findings, ZAS3 appears to be the central regulator
of osteoclastogenesis, warranting further delineation of its role in
diseases where skeleton is compromised due to osteoclast
hyperactivity.
Materials and Methods
Mice, reagents and antibodies
The generation of ZAS3 knockout mice has been described
[15]. Mice, +/+, +/2 and 2/2, used in this study were generated
by +/2 crosses, and most experiments were performed with sex-
matched littermates. Use and care of mice in this study were
approved by the Ohio State University Institutional Animal Care
and Use Committee (Protocol Number 2008A0034). Recombinant
Figure 6. ZAS3 promotes RANKL-mediated osteoclastogenesis and expression of osteoclast-associated genes. RAW264.7 cells (from
500 to 2500 cells) were stably transfected with the empty vector (EV) or the ZAS3 expression construct. (A) Indicated cells were plated onto wells of a
24-well plate and cultured in complete medium supplemented with sRANKL (50 ng/ml) for 6 days, and stained for TRAP. TRAP+ cells with 3 or more
nucleic were considered as OLC and counted. Bar charts show the numbers of OLC. (B) Indicated cells were incubated with sRANKL (50 ng/ml) for 0, 2,
4, or 8 days. The induction of ZAS3, TRAP and CTSK (osteogenic markers), and HSP90 (loading control) was examined in total cell lysates by Western
blot analysis. (C) Indicated cells were incubated with sRANKL (50 ng/ml) for 6 days and the induction of TRAF-6, RelB, c-Fos, and c-Jun was analyzed
by Western blot analysis. (D) EMSA was performed with
32P-GTTCTGGGGAAGTCCAGTGCTCACATGACC DNA probe corresponding to the mouse TRAP
gene enhancer (ZAS3 binding site is shown in underline) and nuclear extracts prepared from indicated cells. The major DNA-protein complexes are
designed C1 to C4. Complex C4 (indicated with a black arrow) was observed only in the ZAS3 transfected samples (lane 3). The formation of C2
(indicated with a grey arrow) and C4 was abolished by the addition of ZAS3 antibodies to the binding reactions (lanes 4 and 5).
doi:10.1371/journal.pone.0017161.g006
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ZAS3 antibodies have been described [4], and other antibodies
were purchased from Santa Cruz Biotechnology, CA.
Bone histomorphometry and mechanical testing
Biomechanical properties of femurs were evaluated by three-
point bending test on a servo hydraulic material test frame using
an MTS 858 Bionix Testing Machine (MTS Systems Corporation,
MN) at 1 mm/min with continuous recording of load until failure.
After mechanical testing, cross-sectional geometry [inner diameter
(I) and outer diameter (O)] at mid-diaphysis were obtained using
a hand-held digital caliper, and area was calculated [area=
p(O
22I
2)/4]. Histomorphometric analyses were performed by
The Bone Histomorphometry Core Laboratory of the University
of Texas, MD Anderson Cancer Center, and The OSU
Mineralized Tissue Mechanics Laboratory. Consistent results
were obtained from both facilities. For bone formation analysis,
mice were injected intraperitoneally with calcein (Sigma-Aldrich,
MO) (20 mg/kg) on day 1 and day 4, and bone harvested on
day 6.
Osteoclast cultures and TRAP staining
Bone marrow stromal cells of 4- to 10-week-old mice were
flushed from femurs and cultured with complete medium
supplemented with M-CSF (50 ng/ml) for 3 days for macrophage
differentiation. Non-adherent cells were further cultured with the
addition of sRANKL (50 ng/ml) to induce osteoclast formation.
TRAP staining of femurs was performed by the OSU Compre-
hensive Cancer Center Comparative Pathology & Mouse
Phenotyping Shared Resource, and of cells was performed using
a leukocyte acid phosphatase kit (Sigma-Aldrich, MO). TRAP-
positive cells containing three or more nuclei were considered as
OLC and counted manually under a light microscope.
Transfection of RAW 264.7 cells
A mammalian expression construct encoding amino acids 106
to 2013 of the ZAS3 protein has been described [11]. On-target
plus
Smart pool siRNAs containing a mixture of 4 oligonucleotides
with potential for mouse ZAS3 (HIVEP3) mRNA destruction by
RISC complexes was used to silence ZAS3 (Thermo Scientific,
MA). SiRNA oligonucleotides or plasmid constructs were
introduced into RAW 264.7 cells (3610
6 cells) by Nucleofector
transfection Kit (Amaxa, MD) according to the manufacturer’s
protocol. A mixture of 4 scrambled siRNAs was used as the
negative control. Following transfection, cells were grown in
RPMI containing 10% fetal bovine serum, M-CSF (50 ng/ml),
and sRANKL (50 ng/ml) on microscopic slides or 6 cm tissue
culture plates. Cells were harvested 4 days later and analyzed for
the ZAS3 knockdown by RT-PCR and Western blot analysis.
Cells stably transfected with the ZAS3 constructs were selected
with G418 (0.4 mg/ml) and incorporation of the constructs was
validated by PCR of genomic DNA.
Figure 7. ZAS3 associates with TRAF6. (A) RAW264.7 cells were incubated with sRANKL (50 ng/ml) for 2 days and immunoprecipitation (IP)
experiment was performed. Protein lysates were incubated with ZAS3 antibodies, washed excessively, and input (I), flow through (FT); wash 1 (W1),
wash 3 (W3), wash 5 (W5), and eluates of immunoprecipitated proteins (E) were subjected to Western blot analysis. Immunoblottings (IB) were
performed with TRAF6 or ZAS3 antibodies. (B) RAW 264.7 cells were treated and IP was performed as described in (A). Protein lysates were IP with
ZAS3 antibodies, TRAF6 antibodies or control IgGs as indicated on the top of each lane, and Western blot analysis was performed with ZAS3
antibodies to show the presence of ZAS3 in both the immunoprecipitates of ZAS3 and TRAF6 antibodies samples, and its absence in control IgG
sample. (C) Putative TRAF6 binding sites in the ZAS3 protein. Top, amino acid sequence alignment showing the TRAF6-binding motif [25] matched
with 6 regions in the ZAS3 protein. Ar, an aromatic and Ac an acidic amino acid residue. Bottom, a diagram showing the locations of the six putative
TRAF6-binding sites in the ZAS3 protein. The localizations of the zinc fingers in the ZAS3 protein were also shown.
doi:10.1371/journal.pone.0017161.g007
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immunohistochemistry
Western blotting and immunohistochemistry of cells on slides
were performed as described [33,34]. For immunoprecipitation,
protein lysates were prepared from RAW 264.7 cells incubated
with sRANKL (50 ng/ml) for 2 days. Target proteins were
immunoprecipitated by incubating total lysates with the relevant
antibodies using Catch and Release v2.0 Reversible Immunopre-
cipitation System (Millipore, Temecula, CA) with the following
modifications. Cell lysate, antibodies and antibody capture affinity
ligand were incubated at 4uC for 16 hours, and the column was
washed with wash buffers for 5 times.
RNA analysis
RNA was prepared using TRIzol reagent and reverse
transcribed by Superscript III reverse transcriptase (Invitrogen,
CA). Standard PCR was conducted and b-actin levels were used as
controls [35]. Sequences of PCR primers: TRAP-F: 59-TGAC-
CACAACCTGCAGTATC-39; TRAP-R: 59CCCAGGGAGTC-
CTCAGATCC-39; CTSK-F: 59-AAGTGGTTCAGAAGATGA-
CGGGAC-39; CTSK-R: 59-TCTTCAGAGTCAATGCCT CC-
GTTC-39; b-Actin-F: 59-CCGGGACCTGACAGACTACC; b-
Actin-R: 59-TGCCACAGGATTCCATACCC; ZAS3-F: 59-
TCCTGAGATCTAAGCAGAAG-39 and ZAS3-R: 59-GAGTC-
TGAGTCAGAGTCCTC-39.
EMSA and antibody gel supershift assays
Nuclear extracts was prepared with a Nuclear Extract Kit
according to manufacturer instructions (Active Motif, Carlsbad,
CA). EMSA with nuclear extracts (2–5 mg) and
32P-labeled DNA
probes were performed as described [36]. The sense strand
oligonucleotide, representing the mouse TRAP proximal sequenc-
es, was 59-TTCTGGGGAAGTCCAGTGCTCACATGACCC-
A-39, and AP-1 was 59-CCGGATTGACTCACGCTTCCAC-39.
Complementary oligonucleotides were annealed and labeled with
32P-dCTP and Klenow. In antibody gel supershift assays, after
incubating protein and DNA probes for 10 minutes, ZAS3
antibodies were added and the binding reactions were incubated
for another 15 minutes before gel loading.
Statistics
Data were expressed as mean 6 SD. Statistical significance was
determined by 2-tailed Student’s t test using Microsoft Excel.
P,0.05 was considered statistically significant.
Figure 8. Molecular targets of ZAS3 in RANK signaling. Shown is a schematic diagram depicting the multiple targets of ZAS3 involved in
the regulation of RANK signaling, important for osteoclastogenic differentiation and function. Binding of RANKL to RANK activates cytoplasmic
ZAS3 that (i) induces expression of TRAF6 and association of ZAS3 and TRAF6 leading to the recruitment of TGF-b-activated kinase 1 (TAK1)
binding protein 2/3 (TAB2/3) to polyubiquitinated TRAF6, which in turn activates TAB1/TAK1, inhibitor of NF-kB alpha (IkBa) kinase (IKK)
complexes, and nuclear translocation of NF-kB p50/p65; (ii) Simultaneously, ZAS3 activates mitogen-activated protein kinases to activate the
transcription factor AP-1 via phosphorylation of p38 and assembly of c-Jun/Fos; (iii) ZAS3 associates with c-Jun to activate AP1 [13]; (iv) ZAS3
itself can act as a transcription factor, i.e., it translocates into the nucleus and binds to gene regulatory elements to activate transcription of
osteoclast-associated genes, such as TRAP and CTSK, and probably NFATc1; and (iv) through the activation of NF-kB, ZAS3 also activates NFATc1
that is shown to integrate sRANKL signaling in the terminal differentiation of osteoclasts [30]. Additionally, ZAS3 mobilizes intracellular calcium,
probably through one of its target genes, the calcium binding protein S100A4/mts1 [4], to activate calcineurin causing the dephosphorylation
and nuclear translocation of NFATc1. ZAS3 individually, or in a transcriptional complex in conjunction with NTAFc1 and NF-kB through
association with AP-1 drives the transcription program for osteoclast differentiation. Important signaling molecules, transcription factors, or
enzymes involved in RANK signaling whose expression levels or protein-protein interactions shown here to be regulated by ZAS3 are indicated
with asterisks.
doi:10.1371/journal.pone.0017161.g008
ZAS3 Is Required for Osteoclastogenesis
PLoS ONE | www.plosone.org 11 March 2011 | Volume 6 | Issue 3 | e17161Author Contributions
Conceived and designed the experiments: LCW SL SA. Performed the
experiments: LCW SL FM CEA JC EH CK AL CJH SH SA JY. Analyzed
the data: LCW SL FM KVH CK AL GM SH SA JY MAC. Contributed
reagents/materials/analysis tools: LCW SL CK AL. Wrote the paper:
LCW SA.
References
1. Wu LC (2002) ZAS: C2H2 zinc finger proteins involved in growth and
development. Gene Expr 10: 137–152.
2. Allen CE, Wu LC (2004) ZAS zinc finger proteins: the other kappa-B-binding
protein family. In: Zinc finger proteins from atomic contact to cellular function
ShiroIuchi, NatalieKuldell, eds. GeorgetownTexas: Landes Bioscience. pp
233–261.
3. Wu LC, Mak CH, Dear N, Boehm T, Foroni L, et al. (1993) Molecular cloning
of a zinc finger protein which binds to the heptamer of the signal sequence for
V(D)J recombination. Nucleic Acids Res 21: 5067–5073.
4. Hjelmsoe I, Allen CE, Cohn MA, Tulchinsky EM, Wu LC (2000) The kappa B
and V(D)J Recombination Signal Sequence Binding Protein KRC Regulates
Transcription of the Mouse Metastasis-associated Gene S100A4/mts1. J Biol
Chem 275: 913–920.
5. Fan CM, Maniatis T (1990) A DNA-binding protein containing two widely
separated zinc finger motifs that recognize the same DNA sequence. Genes Dev
4: 29–42.
6. Yang X, Li J, Qin H, Yang H, Li J, et al. (2005) Mint represses transactivation of
the type II collagen gene enhancer through interaction with alpha A-crystallin-
binding protein 1. J Biol Chem 280: 18710–18716.
7. Dorflinger U, Pscherer A, Moser M, Rummele P, Schule R, et al. (1999)
Activation of somatostatin receptor II expression by transcription factors MIBP1
and SEF-2 in the murine brain. Mol Cell Biol 19: 3736–3747.
8. Makino R, Akiyama K, Yasuda J, Mashiyama S, Honda S, et al. (1994) Cloning
and characterization of a c-myc intron binding protein (MIBP1). Nucleic Acids
Res 22: 5679–5685.
9. Jin W, Takagi T, Kanesashi SN, Kurahashi T, Nomura T, et al. (2006)
Schnurri-2 controls BMP-dependent adipogenesis via interaction with Smad
proteins. Dev Cell 10: 461–471.
10. Shukla A, Malik M, Cataisson C, Ho Y, Friesen T, et al. (2009) TGF-beta
signalling is regulated by Schnurri-2-dependent nuclear translocation of CLIC4
and consequent stabilization of phospho-Smad2 and 3. Nat Cell Biol 11:
777–784.
11. Yakovich AJ, Jiang B, Allen CE, Du J, Wu LC, et al. (2011) ZAS3 accentuates
transforming growth factor beta signaling in epithelial cells. Cell Signal 23:
105–113.
12. Oukka M, Kim ST, Lugo G, Sun J, Wu LC, et al. (2002) A mammalian
homolog of Drosophila schnurri, KRC, regulates TNF receptor-driven responses
and interacts with TRAF2. Mol Cell 9: 121–131.
13. Oukka M, Wein MN, Glimcher LH (2004) Schnurri-3 (KRC) interacts with c-
Jun to regulate the IL-2 gene in T cells. J Exp Med 199: 15–24.
14. Jones DC, Wein MN, Oukka M, Hofstaetter JG, Glimcher MJ, et al. (2006)
Regulation of adult bone mass by the zinc finger adapter protein Schnurri-3.
Science 312: 1223–1227.
15. Allen CE, Richards J, Muthusamy N, Auer H, Liu Y, et al. (2007) Disruption of
ZAS3 in mice alters NF-kappaB and AP-1 DNA binding and T-cell
development. Gene Expr 14: 83–100.
16. Saita Y, Takagi T, Kitahara K, Usui M, Ezura Y, et al. (2007) Lack of schnurri-
2 expression associates with reduced bone remodeling and osteopenia. J Biol
Chem 282: 12907–15.
17. Jones DC, Schweitzer MN, Wein M, Sigrist K, Takagi T, et al. (2010)
Uncoupling of growth plate maturation and bone formation in mice lacking both
Schnurri-2 and Schnurri-3. Proc Natl Acad Sci U S A 107: 8254–8258.
18. David JP, Sabapathy K, Hoffmann O, Idarraga MH, Wagner EF (2002) JNK1
modulates osteoclastogenesis through both c-Jun phosphorylation-dependent
and -independent mechanisms. J Cell Sci 115: 4317–4325.
19. Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue J, et al. (2004) Critical
roles of c-Jun signaling in regulation of NFAT family and sRANKL-regulated
osteoclast differentiation. J Clin Invest 114: 475–484.
20. Novack DV, Teitelbaum SL (2008) The osteoclast: friend or foe? Annu Rev
Pathol 3: 457–484.
21. Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M (2000) Involvement of
p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis
mediated by receptor activator of NF-kappa B ligand (sRANKL). J Biol Chem
275: 31155–31161.
22. Nakabayashi Y, Wevers HW, Cooke TD, Griffin M (1994) Bone strength and
histomorphometry of the distal femur. J Arthroplasty 9: 307–315.
23. Hu R, Sharma SM, Bronisz A, Srinivasan R, Sankar U, et al. (2007) Eos, MITF,
and PU.1 recruit corepressors to osteoclast-specific genes in committed myeloid
progenitors. Mol Cell Biol 27: 4018–4027.
24. Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, et al. (1999) TRAF6
deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS
signaling. Genes Dev 13: 1015–1024.
25. Ye H, Arron JR, Lamothe B, Cirilli M, Kobayashi T, et al. (2002) Distinct
molecular mechanism for initiating TRAF6 signalling. Nature 418: 443–447.
26. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, et al. (1999)
Modulation of osteoclast differentiation and function by the new members of the
tumor necrosis factor receptor and ligand families. Endocr Rev 20: 345–357.
27. Liang J, Lints R, Foehr ML, Tokarz R, Yu L, et al. (2003) The Caenorhabditis
elegans schnurri homolog sma-9 mediates stage- and cell type-specific responses
to DBL-1 BMP-related signaling. Development 130: 6453–6464.
28. Dai H, Hogan C, Gopalakrishnan B, Torres-Vazquez J, Nguyen M, et al. (2000)
The zinc finger protein schnurri acts as a Smad partner in mediating the
transcriptional response to decapentaplegic. Dev Biol 227: 373–387.
29. Baldridge D, Shchelochkov O, Kelley B, Lee B (2010) Signaling pathways in
human skeletal dysplasias. Annu Rev Genomics Hum Genet 11: 189–217.
30. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, et al. (2005) Autoamplification
of NFATc1 expression determines its essential role in bone homeostasis. J Exp
Med 202: 1261–1269.
31. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, et al. (2002) Induction
and activation of the transcription factor NFATc1 (NFAT2) integrate sRANKL
signaling in terminal differentiation of osteoclasts. Dev Cell 3: 889–901.
32. Hirotani H, Touhy N, Woo JT, Stern PH, Clipstone NA (2004) The
calcineurin/NFAT signaling pathway regulates osteoclastogenesis in RAW
264.7 cells. J Biol Chem 279: 13984–13992.
33. Liu S, Wu LC, Pang J, Santhanam R, Schwind S, et al. (2010) Sp1/NFkappaB/
HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer
Cell 17: 333–347.
34. Wu LC, Goettl VM, Madiai F, Hackshaw KV, Hussain SR (2006) Reciprocal
regulation of nuclear factor kappa B and its inhibitor ZAS3 after peripheral
nerve injury. BMC Neurosci 7: 4.
35. Liu S, Liu Z, Xie Z, Pang J, Yu J, et al. (2008) Bortezomib induces DNA
hypomethylation and silenced gene transcription by interfering with Sp1/NF-
kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia.
Blood 111: 2364–2373.
36. Hong JW, Allen CE, Wu LC (2003) Inhibition of NF-kappaB by ZAS3, a zinc-
finger protein that also binds to the kappaB motif. Proc Natl Acad Sci USA 100:
12301–12306.
ZAS3 Is Required for Osteoclastogenesis
PLoS ONE | www.plosone.org 12 March 2011 | Volume 6 | Issue 3 | e17161